Wavelight riding high on new Eye-Q approval

Article

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

The Eye-Q wavefront-guided LASIK procedure has been approved for the reduction or elimination of up to -7.00 D of spherical equivalent (SE) of myopia or myopia with astigmatism, with up to -7.00 D of spherical component and up to 3.00 D of astigmatic component at the spectacle plane.

The Eye-Q system has also been approved by the US regulatory body for the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.